Collegium Pharmaceutical, Inc. COLL Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $62.87M-9.1% | $69.19M+43.7% | $48.16M+289% | -$25.46M-136% | ||
| $4.18M+8.5% | $3.86M+10.3% | $3.5M+30.3% | $2.68M+54.6% | ||
| $41.91M+29.3% | $32.4M+19.4% | $27.14M+18.6% | $22.87M-5.7% | ||
| -$25.66M+4.3% | -$26.81M-1,145% | -$2.15M— | —— | ||
| $5.34M-11.2% | $6.02M-30.3% | $8.64M+4.2% | $8.29M+143% | ||
| -$17.2M-481% | $4.52M— | —— | —— | ||
| $5.45M+139% | -$13.93M— | —— | -$48.27M— | ||
| —— | -$12.09M-339% | $5.06M+816% | -$707K+88.2% | ||
| —— | —— | $628K— | —— | ||
| $7.97M-43.4% | $14.07M+1,078% | -$1.44M-131% | $4.61M+324% | ||
| —— | $0— | $0— | —— | ||
| —— | $165.3M+13.4% | $145.76M— | —— | ||
| -$1.18M+59.4% | -$2.91M— | $0— | —— | ||
| $329.32M+53.9% | $213.98M-22.1% | $274.75M+121% | $124.23M+20.0% | ||
| $1.74M+5.3% | $1.65M+258% | $461K-71.6% | $1.62M-16.6% | ||
| -$63.53M+77.9% | -$287.76M-306% | -$70.81M+87.7% | -$573.69M-29,411% | ||
| $635.56M+490% | $107.81M-33.7% | $162.5M— | —— | ||
| $4.28M-58.2% | $10.25M+18.6% | $8.64M-26.8% | $11.81M-1.2% | ||
| $12.85M-33.0% | $19.17M+129% | $8.36M+107% | $4.04M-2.5% | ||
| —— | $0— | $0— | —— | ||
| -$110.25M— | —— | -$140.18M— | —— | ||
| $155.55M— | —— | —— | —— | ||
| $68.76M+10.1% | $62.43M-14.8% | $73.26M+39.5% | $52.53M+198% | ||
| $60.04M+15.3% | $52.09M+115% | $24.21M+133% | $10.4M+246% | ||
| $1.07M-47.1% | $2.03M— | —— | —— | ||
| $5.34M-11.2% | $6.02M-30.3% | $8.64M+4.2% | $8.29M+143% | ||
| —— | $165.3M+13.4% | $145.76M— | —— | ||
| -$1.18M+59.4% | -$2.91M— | $0— | —— | ||
| $4.18M+8.5% | $3.86M+10.3% | $3.5M+30.3% | $2.68M+54.6% | ||
| $2.85M— | —— | —— | —— | ||
| $7.97M-43.4% | $14.07M+1,078% | -$1.44M-131% | $4.61M+324% | ||
| —— | —— | —— | —— | ||
| —— | -$94K+66.4% | -$280K— | —— | ||
| —— | —— | —— | —— | ||
| $635.56M+490% | $107.81M-33.7% | $162.5M— | —— | ||
| $319K+72.4% | $185K— | —— | —— | ||
| $0-100% | $4.1M— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $0-100% | $99K-78.3% | $457K— | —— | ||
| $60.04M+15.3% | $52.09M+115% | $24.21M+133% | $10.4M+246% | ||
| $327.58M+54.1% | $212.57M-22.5% | $274.29M+124% | $122.61M+20.7% | ||
| $327.58M+54.1% | $212.57M-22.5% | $274.29M+124% | $122.61M+20.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Collegium Pharmaceutical, Inc. generate?
- Collegium Pharmaceutical, Inc. (COLL) generated $331.0M in operating cash flow over the trailing twelve months.
- What is Collegium Pharmaceutical, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Collegium Pharmaceutical, Inc.'s free cash flow was $329.8M over the trailing twelve months, up 60.3% year over year.
- Where does Collegium Pharmaceutical, Inc.'s cash flow data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
